1. The tax information contained in this section is intended to provide the reader with an overview of all taxes contributed by Johnson & Johnson, and not just income taxes. It should be read in conjunction with the Company’s tax information filed with the Securities and Exchange Commission (SEC), including in the most recently filed Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. This tax information is supplemental to, and not a substitute for, the information reported in the Company’s SEC filings.
2. Authorization approval status of our COVID-19 vaccine varies by country. For the latest updates, please visit Janssen.com for additional information.
4. Comparison based on a weighted average of the procedure time with QDOT MICROTM Technology in QMODE (129.8 min; N = 42) and in QMODE+™ (105.2 min; N = 52), and the weighted average of the procedure time with irrigated, contact force RF catheters (202.8 min; 5 studies, N = 622). Comparison of non-randomized, independent single-arm studies.
5. https://www.unaids.org/en/resources/fact-sheet Accessed Feb, 2021.
6. This combined treatment regimen is marketed as CABENUVA in North America.
7. N. Gumede and E. Durden. Johnson & Johnson, Global Public Health, South Africa. Insights on youth leadership in HIV programming for adolescent girls and young women in South Africa: Lessons from programme implementation. https://dreamstaa.co.za/wp-content/uploads/2021/02/Screenshot-2021-02-24-at-16.35.33.png.
9. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf Accessed Mar, 2021.
10. Nature Microbiology. “Tracking virus outbreaks in the twenty-first century.” 2019; 4(1):10-19.
11. Johnson & Johnson also acknowledges its many strategic partners in the ongoing global clinical program for the vaccine regimen, including Bavarian Nordic A/S, Centre Muraz, College of Medicine and Allied Health Sciences, Democratic Republic of the Congo Ministry of Public Health, Emory University’s Project San Francisco, Epicentre, Grameen Foundation, Inserm, Inserm Transfert, Institut National de Recherche Biomédicale, London School of Hygiene & Tropical Medicine, Médecins Sans Frontières, Republic of Rwanda Ministry of Health, Rinda Ubuzima, Rwanda Biomedical Center, Sierra Leone Ministry of Health and Sanitation, Uganda Virus Research Institute, Université de Kinshasa, University of Antwerp, University of Oxford, Walter Reed Army Institute of Research, World Health Organization, World Vision Ireland, Wellcome Trust, Coalition for Epidemic Preparedness Innovations, Vibalogics, and all the people who participated in clinical trials during the Ebola epidemic in West Africa and the DRC.
13. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance Accessed February, 2021.
14. Economist Intelligence Unit (EIU) Report: "It’s Time to End Drug-Resistant Tuberculosis: The case for action." 2019 Available here: https://www.eiu.com/graphics/marketing/pdf/its-time-to-end-drug-resistanttuberculosis-fullreport.pdf. Last accessed 22 September 2020.
15. "A Road Map for Neglected Tropical Diseases 2021–2030," WHO, Executive Summary, page xii https://www.who.int/publications/i/item/9789240010352.
Accessed February, 2021.
20. Chen, Xi, PhD. Decision Resources Group. "Medtech 360: Reprocessed Devices | Market Analysis | US | 2016." Millennium Research Group, Inc., August 2016.
21. Our Sustainable Procurement Program (SPP) was renamed as Supplier Sustainability Program (SSP).
22. Materiality, as used in this Report, and our PTA process are different than the definition used in the context of filings with the Securities and Exchange Commission.